Login to Your Account

FDA OKs Rhucin Phase III for Angioedema Under SPA

By Nuala Moran

Friday, August 5, 2011
LONDON – Pharming Group NV has the all-clear to start treating patients in the U.S. Phase IIIb study of Rhucin in the treatment of acute attacks of angioedema after reaching agreement with the FDA to expand the trial and modify the way the primary endpoint is assessed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription